Concepedia

Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer

Jarey H. Wang, Matthew P. Deek, Adrianna A. Mendes, Yang Song, Amol C. Shetty, Soha Bazyar, Kim Van der Eecken, Emmalyn Chen, Timothy N. Showalter, Trevor J. Royce,

Radiotherapy and Oncology · 2024 · 16 citations · 15 references

DOIFull text

Open access

Abstract

The ArteraAI MMAI biomarker is prognostic for OS and TTCRPC among patients with omCSPC and may predict for response to MDT. Further work is needed to validate the MMAI biomarker in a broader mCSPC cohort.

References

15

Cancer statistics, 2023

Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al. · CA A Cancer Journal for Clinicians · 2023 · 16.1K citations · Full text

, , +23

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial

Piet Ost, Dries Reynders, Karel Decaestecker et al. · Journal of Clinical Oncology · 2017 · 1.3K citations

, , +12

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma, Robert Olson, Stephen Harrow et al. · Journal of Clinical Oncology · 2020 · 1.2K citations · Full text

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

Ryan Phillips, William Y. Shi, Matthew P. Deek et al. · JAMA Oncology · 2020 · 1.1K citations · Full text

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

Matthew P. Deek, Kim Van der Eecken, Philip Sutera et al. · Journal of Clinical Oncology · 2022 · 222 citations · Full text